Bank of New York Mellon
AGRX

Bank of New York Mellon’s Agile Therapeutics AGRX Stock Holding History

Bank of New York Mellon’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20
Closed -$9K – 4745
2022
Q1 		$9K Hold
20
– – ﹤0.01% 4646
2021
Q4 		$20K Hold
20
– – ﹤0.01% 4586
2021
Q3 		$39K Sell
20
-6
-23% -$13.6K ﹤0.01% 4470
2021
Q2 		$69K Sell
26
-72
-73% -$237K ﹤0.01% 4279
2021
Q1 		$408K Sell
98
-1
-1% -$5.41K ﹤0.01% 3797
2020
Q4 		$568K Sell
99
-5
-5% -$29.4K ﹤0.01% 3558
2020
Q3 		$634K Sell
104
-1
-1% -$5.73K ﹤0.01% 3371
2020
Q2 		$584K Buy
105
+77
+275% +$400K ﹤0.01% 3399
2020
Q1 		$103K Buy
28
+1
+4% +$5.74K ﹤0.01% 3853
2019
Q4 		$135K Buy
27
+12
+80% +$41.9K ﹤0.01% 3983
2019
Q3 		$36K Hold
15
– – ﹤0.01% 4146
2019
Q2 		$45K Hold
15
– – ﹤0.01% 4132
2019
Q1 		$47K Sell
15
-1
-6% -$2.12K ﹤0.01% 4101
2018
Q4 		$18K Hold
16
– – ﹤0.01% 4168
2018
Q3 		$11K Hold
16
– – ﹤0.01% 4227
2018
Q2 		$15K Sell
16
-1
-6% -$3.51K ﹤0.01% 4189
2018
Q1 		$89K Sell
17
-2
-11% -$13.2K ﹤0.01% 4083
2017
Q4 		$105K Buy
19
+10
+111% +$93.1K ﹤0.01% 4088
2017
Q3 		$81K Sell
9
-1
-10% -$7.68K ﹤0.01% 4034
2017
Q2 		$71K Sell
10
-18
-64% -$125K ﹤0.01% 4085
2017
Q1 		$182K Sell
28
-4
-13% -$20.1K ﹤0.01% 3903
2016
Q4 		$361K Buy
32
+1
+3% +$14K ﹤0.01% 3718
2016
Q3 		$434K Sell
31
-1
-3% -$14.3K ﹤0.01% 3607
2016
Q2 		$484K Buy
32
+3
+10% +$41.1K ﹤0.01% 3554
2016
Q1 		$355K Buy
29
+8
+38% +$103K ﹤0.01% 3572
2015
Q4 		$408K Hold
21
– – ﹤0.01% 3616
2015
Q3 		$282K Buy
21
+5
+31% +$88.8K ﹤0.01% 3796
2015
Q2 		$272K Buy
+16
New +$341K ﹤0.01% 3808

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon's AGRX Position: Q2 2022 in Review

Bank of New York Mellon sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 20 shares — an estimated $9K sold.

Bank of New York Mellon first reported a position in AGRX in Q2 2015 and held it in 28 quarters. The position peaked at $634K in Q3 2020. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

  • Bank of New York Mellon reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 20 Agile Therapeutics shares in Q2 2022, an estimated $9K.
  • Bank of New York Mellon first reported a position in Agile Therapeutics in Q2 2015 and held it in 28 quarters.
  • Bank of New York Mellon's Agile Therapeutics position peaked at $634K in Q3 2020.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.